Checkmate Pharmaceuticals Inc
NASDAQ:CMPI
Intrinsic Value
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CMPI.
Checkmate Pharmaceuticals Inc's market capitalization is 227.1m USD.
CMPI stock price is 10.5 USD.
CMPI.
CMPI. Open DCF Valuation
CMPI. Open Relative Valuation
CMPI.
CMPI has negative Free Cash Flow for the last twelve months.
CMPI's ROE (Return on Equity) has increased in the last 3 years from -77% to -75%, and is approaching profitability.
CMPI has negative Operating Income for the last twelve months.
CMPI has negative Net Income for the last twelve months.
CMPI's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -282% to -360%, and is approaching profitability.
CMPI's ROE (Return on Equity) for the past 12 months is negative and is equal to -75%.
CMPI's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -360%.
CMPI has negative three-year average ROE (Return on Equity): -296%. The company is not efficient at transforming stockholders' equity into net income.
CMPI has very high three-year average ROIC (Return on Invested Capital): 778%. The company is very efficient at using invested capital to generate operating income.
CMPI's short-term assets (62m USD) exceed its short-term liabilties (12m USD).
CMPI's long-term assets (67m USD) exceed its long-term liabilties (12m USD).
CMPI's D/E (Debt to Equity) is very low and is equal to 0.
CMPI's Altman Z-Score is very low and is equal to -4.37.
Fundamental Analysis
Checkmate Pharmaceuticals Inc
Balance Sheet Decomposition
Checkmate Pharmaceuticals Inc
| Current Assets | 62.1m |
| Cash & Short-Term Investments | 60m |
| Other Current Assets | 2.1m |
| Non-Current Assets | 4.8m |
| PP&E | 730k |
| Other Non-Current Assets | 4.1m |
| Current Liabilities | 11.9m |
| Accounts Payable | 3.6m |
| Accrued Liabilities | 8.3m |
Earnings Waterfall
Checkmate Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-63.2m
USD
|
|
Operating Income
|
-63.2m
USD
|
|
Other Expenses
|
20k
USD
|
|
Net Income
|
-63.2m
USD
|
Free Cash Flow Analysis
Checkmate Pharmaceuticals Inc
What is Free Cash Flow?
CMPI Profitability Score
Profitability Due Diligence
Checkmate Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Checkmate Pharmaceuticals Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
CMPI Solvency Score
Solvency Due Diligence
Checkmate Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Checkmate Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CMPI Price Targets Summary
Checkmate Pharmaceuticals Inc
Ownership
CMPI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CMPI Price
Checkmate Pharmaceuticals Inc
| Average Annual Return | 6% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -89% |
| Market Capitalization | 227.1m USD |
| Shares Outstanding | 22 038 200 |
| Percentage of Shares Shorted | 0.52% |
CMPI News
Last Important Events
Checkmate Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Checkmate Pharmaceuticals Inc
Company Profile
Checkmate Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-08-07. The firm is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. The Company’s product candidate, CMP-001 is a Toll-like receptor 9 (TLR9) agonist delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligonucleotide as a key component. CMP-001 is based on a therapeutic approach, which consists of two components, a capsid protein, which is produced by fermentation, and is derived from a QBeta Ribonucleic acid (RNA) bacteriophage; and a CpG-A deoxyribonucleic acid (DNA) oligonucleotide, which is manufactured by solid phase synthesis. These two components are combined together under controlled conditions where they self-assemble to form the VLP.
You don't have any saved screeners yet
